DUBLIN, Nov. 1, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the presentation of positive new data from several studies of VIBATIV ® (telavancin), the Company's proprietary FDA-approved antibiotic. Results of the studies included reporting of high clinical cure rates in patients with osteomyelitis, greater in vitro potency against challenging MRSA pathogens as compared to other commercialized antibiotics, and similarities in the overall healthcare costs and renal function impact for VIBATIV as compared to vancomycin. These study findings were presented at IDWeek ™ 2016, which was held in New Orleans, LA on October 26 - 30, 2016.
Retrospective Study of Osteomyelitis Patients Reports from a retrospective chart review of 32 osteomyelitis patients treated with VIBATIV in clinical settings in six U.S. medical centers showed 87.5% of patients were considered cured or improved at the end of treatment (EOT). At three months following treatment, the percentage of patients considered cured or improved increased to 91.3%. In this study, Staphylococcus aureus (S. aureus) was the most common pathogen in 18 of those patients (17 methicillin-resistant S. aureus or MRSA and 1 methicillin-susceptible S. aureus or MSSA). The most common side effect observed in the study was nausea, which was reported in 25% of patients and led to discontinuation of therapy in 9.4% of patients. Additionally, 6.7% of patients experienced a two-fold serum creatinine increase, which led to treatment discontinuation for two patients. At EOT, one patient had died due to infection. "Although osteomyelitis is not currently an approved indication for VIBATIV, these encouraging study results merit further investigation and may suggest that osteomyelitis, particularly when caused by MRSA, is another serious infection type against which VIBATIV appears to have had positive clinical outcomes," stated Jon Bruss, M.D., Vice President Clinical Development & Medical Affairs at Theravance Biopharma. "These data, along with interim findings from our ongoing TOUR ™ patient registry which were presented at IDWeek, provide interesting insight into clinical results and prescribing patterns for VIBATIV in real-world settings." Highlights from other VIBATIV data presentations at IDWeek 2016 include: